Related coverage linked through entity extraction aliases.
Jul 19, 2026
Arbutus and Genevant filed three new lawsuits against Pfizer and BioNTech over mRNA vaccine lipid nanoparticle patents, shortly after receiving a $178 million payment from Moderna. Sanofi also launched two separate patent suits against Pfizer and Moderna. A Delaware court previously narrowed Moderna's defenses in a related case.
Apr 25, 2026
BioNTech enters May with first-quarter earnings due May 5 and a May 15 shareholder vote on a capital increase. The company is pushing its oncology pipeline as COVID-19 vaccine sales decline.
Apr 23, 2026
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Mar 08, 2026
Pfizer is applying lessons from its Viagra launch to introduce its first obesity treatment, a monthly injection acquired from Metsera. The company aims to leverage past experience with sensitive health topics as it enters the competitive obesity market.
Feb 23, 2026
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging the company's newly approved mNEXSPIKE vaccine uses proprietary mRNA technology without authorization.
Feb 20, 2026
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging that Moderna's next-generation COVID-19 vaccine mNEXSPIKE violates its mRNA vaccine design patent.
